

INDEX

- Actigraphs, 46–48
- Actigraphy, 45
- chronotherapeutics research and, 51
 - early morning period and, 52–53
 - during sleep, 51–52
 - sleep apnea and, 53–54
- Activity
- ambulatory BP and, 34, 39 *table*
 - blood pressure and, 48–50
 - circadian rhythm in, 95–96
 - heart rate and, 48–50
 - monitoring, *see* Actigraphy
 - sleep and, 51–53
- Adolescents
- diurnal BP profile in, 151–53
 - potassium and, 185–86
 - repeat ABPM and, 157
 - salt sensitivity and, 183
- Adrenocorticotrophic hormone (ACTH)
- circadian rhythm in, 90, 91–92
 - fatal familial insomnia and, 98
- Age
- blood pressure and, 10
 - circadian rhythm in, 95
 - cerebrovascular seasonality and, 244–45
 - heart rate and cardiovascular mortality and, 160
 - nocturnal fall in BP and, 148, 149 *fig.*
- Alcohol
- blood pressure and, 12
- Aldosterone
- circadian rhythm in, 90, 97
 - sleep architecture and, 179–80
 - α -adrenoceptors
 - antagonists, 262–63
 - α -adrenoceptors, 249
- Ambulatory blood pressure (ABP)
- activity and, 34, 39 *table*
 - anger and, 34–35
 - clinic vs., 195–97
- Ambulatory blood pressure (ABP) (*cont.*)
- as continuous variable, 194–95
 - emotional state and, 34, 35, 36 *table*, 38 *table*
 - ethnicity and, 40–41
 - gender differences in, 35, 36 *table*
 - job strain and, 37–40
 - nocturnal fall in
 - salt sensitivity and, 183, 184–85
 - observed vs. predicted, 195–97
 - personality and, 34
 - placebo effect and, 280–83
 - place of measurement and, 38 *table*
 - posture and, 34, 36 *table*, 39 *table*
 - potassium and, 173, 185–86
 - prognostic value of, 192–94
 - salt and, 35, 39 *table*
 - seasonality and, 35
 - smoking and, 197
 - stress and, 40
 - time-of-day and, 33
 - variation in, 32–37
 - work and, 33
- Ambulatory blood pressure monitoring (ABPM), 57, 172, *see also* Blood pressure monitoring (BPM), home
- advantages, 139–40, 294
 - antihypertensive drugs and, 68–69, 274
 - trials, 276–80, 285–90
 - autonomic dysfunction and, 71–72
 - chronotherapeutics and, 70–71, 290–94
 - cost-effectiveness of, 72–73
 - data
 - analysis of, 62–65
 - descriptive, 62–63
 - reporting of, 64–65
 - devices, 257–58
 - advantages vs. disadvantages, 59 *table*, 60

- Ambulatory blood pressure monitoring (ABPM) (*cont.*)
- devices (*cont.*)
 - auscultatory vs. oscillometric, 58–60
 - calibration of, 59
 - oscillometric vs. auscultatory, 58–60
 - patient education in use, 59
 - timing of, 59
 - validation of, 53, 60–62
 - diary-keeping and, 30–32, 33–37, 59
 - drug action duration and, 264
 - environmental conditions, 30, 32
 - indications regarding, 66–72
 - orthostatic hypotension and, 71–72
 - repeatability of, 157
 - reproducibility of, 65–66, 274–76
 - resistant hypertension and, 69–70
- American Association for the Advancement of Medical Instrumentation (AAMI), 6–7, 60
- Amines
- biogenic, *see* Biogenic amines
- Amlodipine, 289–90
- Amplitude
- defined, 81
- Anger
- myocardial infarction and, 223–24
- Angiotensin-converting enzyme (ACE)
- inhibitors, 176–79, 261–62
- Angiotensin II
- circadian rhythms in, 90, 97
- Antihypertensive drug therapy, *see also* Hypertension
- ABPM and, 68–69, 274
 - circadian dosing times, 259
 - delivery systems, 292–94
 - dipping patterns and, 266
 - duration of effect, 264
 - early morning period and, 52
 - evaluation of, 20–22
 - heart rate, 167
 - home monitoring and, 20–23
 - timing of administration, 291–92
 - trials
 - ABPM and, 276–80, 283–90
 - comparator, 288–90
- Antihypertensive drug therapy (*cont.*)
- trials (*cont.*)
 - dose-finding studies, 285–87
 - home monitoring and, 22–23
 - multicenter, 278–80
 - patient evaluation for, 276–77
 - placebo effect and, 280–83
 - white coat hypertension and, 285
 - white coat hypertension and, 202
- Apnea
- sleep, *see* Sleep apnea
- Arrhythmias
- circadian rhythms in, 107, 231–32
- Arteries
- day–night pattern of, 102–103
- Association for the Advancement of Medical Instrumentation (AAMI), *see* American Association for the Advancement of Medical Instrumentation (AAMI)
- Atenolol, 264, 265 *fig.*, 288
- Atherosclerosis
- of coronary arteries
 - day–night pattern of, 103
 - tachycardia and, 159, 162–63
- Atrial natriuretic peptide (ANP), 174
- circadian rhythms in, 93
 - blood pressure and, 96–97
- Auscultatory technique, 8
- Automatic implantable cardioverter-defibrillator (AICD) discharges, 222
- Autonomic nervous system
- activity
 - circadian changes in, 84
 - circadian rhythms and, 87, 97, 102
 - dysfunction
 - ambulatory blood pressure monitoring and, 71–72
- B**
- Belgian population study, 142, 144–48
- Benazepril, 178, 262
- β -adrenoceptors
- antagonists of, 259–60
- Beta-blocker Heart Attack Trial, 230–31

- β -blockers
 congestive heart failure and, 166–67
 heart rate and, 165–66
- Biogenic amines
 circadian rhythms and, 87–90
- Biological rhythms, 81
 defined, 80
- Bisoprolol, 264, 288
- Blood coagulation
 circadian rhythms in 104, 109
- Blood flow
 day–night pattern of, 101–102
- Blood pressure
 activity and, 48–50
 circadian rhythm in, 95–96
 age and, circadian rhythm in, 95
 ambulatory, *see* Ambulatory blood pressure (ABP)
 atrial natriuretic peptide (ANP) and circadian rhythms in, 96–97
 changes in
 day–night, 203–208
 sleep–wake cycle, 204
 circadian, *see* Circadian blood pressure
 clinic, *see also* White coat effect;
 White coat hypertension (WCH)
 ambulatory vs., 195–97
 home vs., 14–16
 placebo effect and, 280–83
 dipping patterns, 51–52, 58, 64, 98–99, 181–82, 205
 hypertension and, 109
 inverse, 58, 71–72
 diurnal profile
 in adolescents, 151–53
 in children, 151–53
 descriptive methods, 140–42
 gender differences in, 144–48
 population determinants, 142–53
 reproducibility of, 155–57
 smoking and, 144–47
 working time and, 153–55
 electrolytes and, 172–73
 ethnicity and
 circadian rhythm in, 95
- Blood pressure (*cont.*)
 heart rate and, 48–50
 home, 16–17, *see also* Ambulatory blood pressure (ABP)
 age and, 10
 alcohol and, 12
 caffeine and, 12–13
 clinic vs., 14–16
 day of week, 12
 demographic factors, 10
 environmental factors, 10–14
 exercise and, 14
 gender and, 10
 meals and, 12
 prognosis and, 19–20
 seasonality, 11
 smoking and, 12–13
 stress and, 13, 18
 talking and, 13
 time of day, 11–12
 load, 63, 283–84
 measurements
 analysis of, 32–33
 monitoring, *see* Ambulatory blood pressure monitoring (ABPM); Blood pressure monitoring (BPM)
 night–day ratio, 140–41
 nocturnal fall in, 97, 98–99, 101, 140–41
 age and, 148, 149 *fig.*
 body mass index and, 148
 cardiac output and, 148
 gender differences and, 148, 149 *fig.*
 hypertension vs. normotension and, 148–50
 nationality and, 148, 149 *fig.*
 recording technique and, 150
 residence and, 150–51
 salt sensitivity and, 182–85
 sleep and, 95
 time of day and, 71 *table*
 ultradian, 208–209
 variations in, 4, 58

- Blood pressure monitoring (BPM), *see also*
 Ambulatory blood pressure
 monitoring (ABPM)
- clinical
- cost-effectiveness, 73
 - devices, *see also* Ambulatory blood
 pressure monitoring
 (ABPM), devices
 - accuracy testing, 7–8
 - aneroid, 5, 7, 8
 - arm, 6
 - choice of, 5–6
 - electronic, 5–6, 7, 8
 - finger, 6
 - mercury sphygmomanometers, 5, 8
 - motion-sensing, 34
 - testing of, 6–7
 - validation of, 6–7
 - wrist, 6
- dipping patterns and, 52
- home, *see also* Ambulatory blood
 pressure monitoring (ABPM)
- antihypertensive treatment and, 20–23
 - cost-effectiveness of, 23–24
 - frequency of readings, 18–19
 - hypertension diagnosis, 17–18
 - medication compliance and, 23
 - reporting on, 9–10
 - reproducibility of, 15–16
 - target organ damage and, 19
 - timing of readings, 18–19
- intra-arterial, 201–202
- office
- reproducibility of, 274–76
 - sleep interference and, 52
- Body mass index
- BP recording techniques and, 150
 - nocturnal fall in BP and, 148
- Bordeu, Théophile de, 256
- Bradycardia, 99, 100, *see also* Heart rate
- British Hypertension Society (BHS), 6–7,
 60–61
- C**
- Caffeine
- blood pressure and, 12–13
- Calcitonin-gene-related peptide (CGRP)
- circadian rhythm in, 94
- Calcium channel blockers, 167, 260–61
- Cardiac Insufficiency Bisoprolol II (CIBIS
 II) trial, 231
- Cardiac output
- nocturnal decrease in, 101
- Cardiovascular disease
- circadian rhythm in, 105–10
- Cardiovascular events
- in early morning, 51
 - hemostatic factors in, 222–23
- Cardiovascular function
- neuroendocrine effectors and, 85–87
 - temporal control of, 84–85
- Cardiovascular hemodynamics
- circadian rhythm in, 101–104
- Cardiovascular physiology
- circadian organization of, 95–105
- Cardiovascular risk
- heart rate and, 159–67
- Cardiovascular system
- chronobiology of, 257–58
 - humoral factors affecting, 90–94
- CASTEL study, 160
- Catecholamines
- circadian rhythm and, 87, 88
- Cerebrovascular events, *see also* Strokes
- circadian rhythm in, 107
- Children
- diurnal blood pressure profile, 151–53
 - repeat ABPM and, 157
- Chronopharmacodynamics, 258–63
- Chronopharmacokinetics, 263–64
- Chronopharmacology
- of angiotensin-converting enzyme
 (ACE) inhibitors, 176–79
- Chronotherapeutic oral drug absorption
 system (CODAS), 292
- Chronotherapeutics, 290–94
- actigraphy and, 51
- Circadian blood pressure, 95–99
- chronic heart failure and, 97
 - electrolytes and, 172–73
 - fatal familial insomnia and, 98
 - genetic component, 96

- Circadian blood pressure, 95–99 (*cont.*)
heart rate and, 99–100
hypertension and, 265
neuro-humoral patterns and, 174–86
plasma renin activity (PRA) and, 175–76
pregnancy and, 95
sleep and, 51–53, 175–76
sympathetic nervous system (SNS) and, 96, 180–82
- Circadian rhythms
in adrenocorticotrophic hormone (ACTH), 90, 91–92
in aldosterone, 90, 97
in angiotensin II, 90, 97
in arrhythmias, 107, 231–33
in arterial vessels, 102–103
in atherosclerotic coronary arteries, 103
in atrial natriuretic peptide (ANP), 93, 174
blood pressure and, 96–97
autonomic nervous system and, 84, 87, 97
biogenic amines and, 87–90
in blood coagulation, 104, 109
in blood flow, 101–102
in blood pressure, *see* Circadian blood pressure
in calcitonin-gene-related peptide (CGRP), 94
in cardiac output, 101
in cardiovascular disease, 105–10
in cardiovascular hemodynamics, 101–104
in cardiovascular physiology, 95–105
in the cardiovascular system, 257–58
in cerebrovascular events, 107
in coronary arteries, 103
disease and, 83–84
dopamine and, 87, 109–10
epinephrine and, 87–88
in fibrinolysis, 104, 109
glucocorticoids and, 98
of heart rate, 99–100
in humoral factors, 90–94, 97
in hyperglycemia, 105
- Circadian rhythms (*cont.*)
in hypothalamic–pituitary–adrenal (HPA) system, 91–92
in hypothalamic–pituitary–thyroid system, 92
monoaminergic mechanisms and, 86
in myocardial infarction, 106, 220–21
in myocardial ischemia, 106
neuroendocrine effectors and, 85–87
norepinephrine and, 87, 88
in the opioid system, 92–93, 97
in plasma renin activity (PRA), 90, 174–76
platelets and, 104, 109
in prorenin, 90
in pulmonary arterial pressure, 102
in renal function, 91
in renin, 90, 97
serotonin and, 87
in stroke onset, 245, 248–49
in sudden cardiac death (SCD), 106, 228–31
in the sympathetic system, 87, 88–89, 96, 97–98
vasoconstriction and, 248–49
vasopressin and, 94
in venous hemodynamics, 103
in venous tone, 102
- Circadian time structure, 82–83
Clock-time-dependent method, 141
Clock-time-independent method, 140
Congestive heart failure
β-blockers and, 166–67
Controlled-onset extended release (COER) (delivery system), 292–93
Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial, 293–94
Coronary arteries
bypass surgery
sleep and, 53
day–night pattern of, 103
Coronary plaque, 226
Coronary thrombosis
theory of, 226–27

- Cosinor method, 142
- Cuff inflation, 8–9
sleep and, 52, 205
- Cumulative-Sum (cusum) Analysis, 141–42
- D**
- Danish Verapamil Infarction Trials (DAVIT I and II), 231
- Defibrillators, implan *table*, 222, 231–32
- Desynchronization, of biological rhythms, 81
- Diaries
ABPM and, 30–32, 33–37, 59
sleep definition and, 52
- Dihydropyridine derivatives, 260
- Diltiazem, 167, 260, 264
- Dipping patterns, 51–52, 58, 64, 98–99, 181–82, 205
antihypertensive drugs and, 266
BPM and, 52
gender differences in, 144–48
hypertension and, 109
inverse, 58, 71–72
normotensives vs. hypertensives, 52
repeat ABPM and, 157
salt sensitivity and, 99
strokes and, 248
- Disease
circadian rhythms and, 83–84
- Dopamine
circadian variations and, 87, 109–10
ultradian variations and, 89–90
- Doxazosin, 262, 263
- E**
- Electrolytes
circadian blood pressure and, 172–73
- Emotional state
ABP and, 34, 35, 36 *table*, 38 *table*
- Enalapril, 20, 21, 177, 178, 262, 263, 264, 265 *fig.*
- Environmental time cues, 81
- Epinephrine, 180
circadian rhythms and, 87–88, 249
ultradian rhythms and, 89–90
- Eplerenone, 286–87
- Eprosartan, 285–86
- Ethnicity, *see also* Nationality
ABP and, 40–41
blood pressure and
circadian rhythm in, 95
- Exercise
blood pressure and, 14
- F**
- Fatal familial insomnia, 98, 99–100
- Fibrinolysis, 222–23, 249
circadian rhythm of, 104, 109
- Fourier method, 142, 143
- Framingham study, 160, 228–29
- G**
- Gender differences
in ABP, 35, 36 *table*
in blood pressure, 10
in cardiovascular morbidity, 98–99
in dipping patterns, 144–48
in diurnal BP profile, 144–48, 152
nocturnal fall in BP and, 148, 149 *fig.*
- Glucocorticoids
fatal familial insomnia and, 98
- H**
- HARVEST, *see* Hypertension and Ambulatory Recording Study (HARVEST)
- Heart
electrical properties, 100–101
- Heart failure
chronic, 97
congestive
 β -blockers and, 166–67
- Heart rate, *see also* Bradycardia; Tachycardia
activity and, 48–50
ambulatory, 209–11
antihypertensive drugs and, 167
 β -blockers and, 165–66
blood pressure and, 48–50
cardiovascular risk and, 159–67
circadian rhythm of, 99–100
clinic vs. ambulatory, 209–11
hypertension and, 160


- Heart rate, *see also* Bradycardia;
Tachycardia (*cont.*)
myocardial infarction and, 160–61
sudden death and, 160
threshold values, 165, 166 *table*
- Hellwig, Christoph, 256
- Hematocrit, 109, 249
- Homeostasis, 80
- Humoral factors
affecting cardiovascular system, 90–94
circadian rhythm in, 90–94, 97
- Hyperglycemia
circadian rhythm in, 105
- Hypertension, 15, 32, *see also*
Antihypertensive drugs
chronopharmacology of, 258–64
circadian BP and, 265
diagnosis, 32
home monitoring and, 17–18
dipping patterns and, 52, 109
heart rate and, 160
nocturnal fall in BP and, 148–50
pathology determination, 32
resistant, 69–70
strokes and, 248
tachycardia and, 159
“white coat,” *see* White coat
hypertension (WCH)
- Hypertension and Ambulatory Recording
Study (HARVEST), 66, 68
- Hypotension
orthostatic
ABPM and, 71–72
- Hypothalamic–pituitary–adrenal (HPA)
system
circadian organization in, 91–92, 97
- Hypothalamic–pituitary–thyroid system
circadian rhythm in, 92
- I**
- Implan *table* cardioverter-defibrillators
(ICDs), 222, 231–32
- Indapamide, 262
- Indoramin, 262
- Infarcts, *see also* Myocardial infarction
acrophases of, 248
- Infradian rhythms, 80
- Insomnia, fatal familial, *see* Fatal familial
insomnia
- Insulin, 105
- Insulin-dependent diabetes mellitus
(IDDM), 105
- Insulin-resistance syndrome
tachycardia and, 163–64
- Intravenous Streptokinase in Acute
Myocardial Infarction Study
(ISAM), 220
- Ischemia, 108
- J, K, L, M**
- Jet lag, 81
- Kaiser Permanente Medical Care Program,
23–24
- Korotkoff sound technique, 6, 7, 58–59
- Left ventricular hypertrophy (LVH), 19,
98–99, 198–99, 205
- Losartan, 288–89
- Medication
compliance with
home monitoring and, 23
- Melatonin, 85, 86
- Microneurography, 180
- Mini-MotionLogger Actigraph, 46–48
- Monoaminergic mechanisms
circadian rhythms and, 86
- Mount Sinai Medical Center, 245, 248
- Moxonidine, 167
- Multicenter Investigation of Limitation of
Infarct Size (MILIS) trial, 224
- Myocardial infarction
anger and, 223–24
circadian rhythm in, 106, 180–81, 220–
21
circannual variation of, 221–22
circaseptan variation of, 221
heart rate and, 160–61
mental stress and, 225–26
onset factors, 222–23
physical exertion and, 224, 225
sexual activity and, 224–25
sleep and, 222
trigger mechanisms, 225

- Myocardial Infarction Onset Study (MIOS), 223, 224
- Myocardial ischemia
circadian rhythm in, 106
- N**
- Nationality, *see also* Ethnicity
nocturnal fall in BP and, 150–51
- National Registry of Myocardial Infarction (NRFMI), 221
- Nervous system
autonomic, *see* Autonomic nervous system
sympathetic, *see* Sympathetic nervous system
- Neuroendocrine effectors, 85–87
- Neuro-humoral patterns
circadian blood pressure and, 174–86
- NHANES study, 160
- Nifedipine, 261, 263
- Nitrendipine, 261
- Norepinephrine, 180
circadian rhythms and, 87, 88
ultradian rhythms and, 89–90
- Normotension, 15
dipping patterns and, 52, 148–50
white coat hypertension and, 58
- O**
- Ohasama study, 10, 17, 19–20, 71–72, 194, 207
- Opioid system
circadian organization in, 92–93, 97
- Orthostatic hypotension
ABPM and, 71–72
- Oscillometry, 5–6, 10
- P**
- Pacemaker clocks, 81
- Perindopril, 178
- Peripheral resistance, 101
- Personality
ABP and, 34
- Physical activity, *see* Activity
- Pineal gland, 85–86, 90
- PIUMA (Progetto Iperensione Umbria Monitoraggio Ambulatoriale) study, 192–93, 198, 199–201
- Plasma K⁺, *see also* Potassium
ABP and, 173
- Plasma renin activity (PRA)
circadian rhythm in, 90, 174–76, 249
- Platelets, 223
circadian rhythm and, 104, 109, 249
- Plethysmographic devices, 257
- Polysomnography, 54
- Posture
ABP and, 34, 36 *table*, 39 *table*
- Potassium, *see also* Plasma K⁺
ABP and, 185–86
- Prazosin, 262
- Pregnancy
blood pressure and
circadian rhythm in, 95
- Propranolol, 263
chronopharmacology of, 260
- Prorenin
circadian rhythm and, 90
- Pulmonary arterial pressure
day–night pattern, 102
- Pulse pressure
clinic vs. ambulatory, 211–12
- Pulse rate
measurement of, 255–57
- Pulsilgium, 256–57
- Q, R, S**
- Q–T interval, 100
- Quinapril, 177–78, 262
- Renal function
circadian rhythm in, 91
- Renin
circadian rhythm in, 90, 97
- Rilmenidine, 167
- Salt
ABP and, 35, 39 *table*
blood pressure and, 182–85
SNS activity and, 183–84
- Salt sensitivity
nocturnal BP fall and, 99

- Sanctorius, Sanctorius, 256–57
- Serotonin
- circadian rhythm and, 87
- Shift work, 81, 95–95, 106
- diurnal BP profile and, 154–55
- Sleep
- actigraphy during, 51–52
 - activity levels during
 - hypertensives vs. normotensives, 52
 - and activity routine, 81
 - aldosterone and, 179–80
 - BP monitors and, 52
 - BP variations during, 51–52, 95
 - coronary artery bypass surgery and, 53
 - cuff inflations and, 52, 205
 - diary methods defining, 52
 - dipping patterns and, *see* Dipping patterns
 - myocardial infarction and, 222
 - non-rapid-eye-movement (NREM), 175
 - plasma renin activity (PRA) and, 175
 - rapid-eye-movement (REM), 95, 108, 175
 - sudden cardiac death (SCD) and, 222
 - sympathetic nervous system (SNS) and, 180–82
 - and wake cycle, 82, 84
- Sleep apnea
- actigraphy and, 53–54
- Smoking
- ABP and, 197
 - blood pressure and, 12–13
 - diurnal BP profile and, 144–47
- Sphygmomanometers, 5, 8–9
- Square-wave method, 141
- Stress
- blood pressure and, 13, 18, 40
 - myocardial infarction and, 225–26
 - sudden cardiac death (SCD) and, 228
- Strokes, 109, *see also* Cerebrovascular events
- age and seasonality in, 244–45
 - circadian variability, 245, 248–49
 - circaseptan variability, 245
 - climate and, 244
 - dipping patterns and, 248
- Strokes (*cont.*)
- hypertension and, 248
 - patterns in, 243–44
 - seasonal variability, 244–45
 - temporal distribution of, 246–47 *table*
 - weather and, 244
- Sudden cardiac death (SCD)
- circadian rhythms in, 106, 228–31
 - clinical variables in, 227–28
 - heart disease and, 228
 - heart failure and, 229
 - noncoronary causes of, 229
 - physical activity and, 225
 - prevention of, 230–31
 - sleep and, 222
 - stress and, 228
- Sudden death
- heart rate and, 160
- Suprachiasmatic nuclei (SCN), 81, 85
- Sympathetic nervous system (SNS)
- circadian blood pressure and, 180–82
 - circadian rhythm in, 96, 97–98
 - salt sensitivity and, 183–84
 - tone
 - day–night pattern of, 87, 88–89
 - ventricular arrhythmias and, 165
- Synchronizers
- in biological rhythms, 81
- Systolic Hypertension in Europe (Syst-Eur) study, 65, 195
- T**
- Tachycardia, *see also* Heart rate
- atherosclerosis and, 159, 162–63
 - cardiovascular events and, 165
 - definition of, 165, 166 *table*
 - hypertension and, 159
 - insulin-resistance syndrome and, 163–64
 - ventricular arrhythmias and, 165, 231–33
- Target organ damage
- home monitoring and, 19
- Task Force on Blood Pressure Control in Children, 152
- Telmisartan, 288–90

- Thrombolysis in Myocardial Infarction II
Trial (TIMI II), 220, 224
- Thrombolysis in Myocardial Ischemia
(TIMI) III Registry, 220
- Thrombosis
theory of, 226–27
- Thyroid stimulating hormone (TSH), 92
- Time above threshold mode (TAT), 46
- Trandalopril, 20–21
- U, V**
- Ultradian rhythms, 80
dopamine and, 89–90
epinephrine and, 89–90
norepinephrine and, 89–90
- Urinary excretion, 172–7
- Vagal tone, 87
- Vasoactive peptides, 93–94, 97
- Vasoconstriction
circadian variation in, 248–49
- Vasopressin
circadian rhythms in, 94
- Venous hemodynamics
circadian change in, 103
- Venous tone
day–night pattern of, 102
- Ventricular arrhythmias, 165, 231–33
- Verapamil, 167, 260, 292–94
- W**
- White coat effect, 4, 58, 63–64, 202–203
- White coat hypertension (WCH), 17, 18,
63–64, 67–68
antihypertensive drugs and, 202, 277,
285
defining, 63–64, 67–68, 197–202
early reports on, 256, 257
normotensive pattern vs., 58
white coat effect vs., 203
- Women
heart rate and cardiovascular mortality,
160
- Work
ABP and, 33
- X, Z**
- Xipamide, 262
- Zadek, J., 257
- Zero crossing mode (ZCM), 46

About the Editor



Dr. William White has been a Professor in the Department of Medicine and Chief of the Section of Hypertension and Clinical Pharmacology at the University of Connecticut School of Medicine for nearly 20 years. In addition, he is an attending physician at the John Dempsey Hospital in Farmington, Connecticut and a consulting physician in hypertension and vascular diseases at the Newington V. A. Medical Center (Newington, CT) and the Connecticut Children's Medical Center (Hartford).

After receiving his medical degree from the Medical College of Georgia, Dr. White completed his residency and chief residency at the University of Connecticut Consortium Hospitals in the greater Hartford area.

Dr. White also completed a research fellowship in cardiovascular pharmacology at the University of Bergen in Norway under the leadership of Professor Per Lund-Johansen. Dr. White is U.S. board certified in both internal medicine and clinical pharmacology.

Dr. White is a Fellow of the American College of Physicians, the Council for High Blood Pressure Research of the American Heart Association, and the International Society for Hypertension in Blacks and a charter member of the American Society of Hypertension.

Dr. White has a long-standing interest in clinical hypertension, ambulatory blood pressure monitoring, and clinical trials of antihypertensive drugs. In 1981, he founded a hypertension unit at the University of Connecticut Health Center that included a faculty consultant practice as well as a clinical trials unit. He is the author or coauthor of over 230 articles and book chapters in the field of hypertension and clinical pharmacology.

In 1996, Dr. White developed the peer-reviewed, international journal *Blood Pressure Monitoring*, which is devoted to original research in the area of blood pressure measurement and variability. The journal is entering its 4th year of publication and has recently been indexed on EMBASE/Excerpta Medica and MEDLINE. He also serves on numerous editorial boards including the *American Journal of Hypertension*, *American Journal of Cardiology*, *American Journal of Medicine*, *Clinical Pharmacology and Therapeutics*, *Journal of Human Hypertension*, and the *American Journal of Clinical Hypertension*.